ChemicalBook >> journal list >> Journal of Clinical Investigation >>article
Journal of Clinical Investigation

Journal of Clinical Investigation

IF: 13.3
Download PDF

Tumor initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice

Published:7 January 2025 DOI: 10.1172/JCI180893 PMID: 39774471
Shuang Chen, Chensong Huang, Kang Li, Maosheng Cheng, Caihua Zhang, Jianqi Xiong, Guoli Tian, Ruoxing Zhou, Rongsong Ling, Xiaochen Wang, Gan Xiong, Zhihui Zhang, Jieyi Ma, Yan Zhu, Bin Zhou, Liang Peng, Zhenwei Peng, Heping Li, Demeng Chen

Abstract

Tumor-initiating cells (TICs) play a key role in cancer progression and immune escape. However, how TICs evade immune elimination remains poorly characterized. Combining single-cell RNA-Seq (scRNA-Seq), dual-recombinase-based lineage tracing, and other approaches, we identified a WNT-activated subpopulation of malignant cells that act as TICs in vivo. We found intensive reciprocal interactions between TICs and immune-regulatory tumor-associated macrophages (Reg-TAMs) via growth arrest-specific 6/AXL receptor tyrosine kinase/MER proto-oncogene, tyrosine kinase (GAS6/AXL/MERTK) signaling pathways, which facilitated the immune escape of TICs. In this study, we used chemical inhibitors and Axl/Mertk conditional double-KO (cDKO) mice to demonstrate that inhibiting the interaction between TIC-derived GAS6 and AXL/MERTK in Reg-TAMs reactivated antitumor immune responses. We identified CCL8 as a critical mediator of the GAS6/AXL/MERTK pathway, primarily by inhibiting Treg infiltration into the tumor. Furthermore, the AXL/MERTK signaling blockade sensitized tumor cells to anti-programmed cell death 1 (anti-PD-1) treatment. Thus, we elucidated a detailed mechanism by which TICs evade tumor immunity, providing insights into strategies to eradicate TICs that escape conventional immunotherapy.

Substances (2)

Materials
Procduct Name CAS Molecular Formula Supplier Price
xav-939 284028-89-3 C14H11F3N2OS 236 suppliers $7.00-$2097.80
xav-939 284028-89-3 C14H11F3N2OS 236 suppliers $7.00-$2097.80

Similar articles

IF:6.9

Role of ginsenoside Rh2 in tumor therapy and tumor microenvironment immunomodulation

Biomedicine & Pharmacotherapy Sun Xiaodan , Cheng Ying,etc Published: 1 December 2022
IF:10.7

Label‐Free Prediction of Tumor Metastatic Potential via Ramanome

Small Methods Yuxing Zhang, Yanmei Zhang,etc Published: 19 November 2024